Santarus reps pushing Naprelan

Share this article:
Santarus said its sales reps will commence promotional activities in the third quarter for Victory Pharma's Naprelan brand products under a recent co-promotion agreement.

Naprelan tablets are a once daily control-release formulation of the non-steroidal anti-
inflammatory drug (NSAID) naproxen sodium, indicated for pain relief caused by a number of conditions including arthritis.

Santarus said it plans to promote Naprelan to targeted primary care physicians. Reps will also continue to promote the company's Rx heartburn treatment Zegerid to gastroenterologists and primary care doctors alongside reps from inVentiv and Otsuka America.  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.